US FDA explores creating drug lifecycle office; lifts generics office to 'super' status
This article was originally published in SRA
The US Food and Drug Administration is exploring the creation of a new Office of Pharmaceutical Quality (OPQ), which would be charged with overseeing quality throughout the lifecycle of a medicine1. The agency has also elevated yet another programme office to the status of "super", meaning it consists of multiple smaller subordinate programmes within its structure, with the Office of Generic Drugs (OGD) the latest to get bumped up to the new ranking.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.